We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Pathogen Reduction Evaluated in Treated Whole Blood

By LabMedica International staff writers
Posted on 21 Feb 2012
Print article
Image: Trypanosoma cruzi in thin blood film (Photo courtesy of US Centers for Disease Control).
Image: Trypanosoma cruzi in thin blood film (Photo courtesy of US Centers for Disease Control).
The survival of a parasite that can be transmitted by blood transfusion has been ascertained in whole blood treated with a commercial system.

The system which uses riboflavin (RB) and ultraviolet (UV) light to inactivate pathogens was used to reduce the levels of infectious Trypanosoma cruzi, the causative agent of Chagas disease in whole blood.

At the American Red Cross (Rockville, MD, USA), scientists inoculated with 4, 40, 400, and 4,000 trypomastigotes/mL into units of whole blood. The blood was transferred to Mirasol illumination bags, with the addition of 35 mL of 500 µmol/L RB solution, and the bag illumination of with UV light. The units were illuminated with 60, 80, and 110 joules/mL of red blood cells, with sample removal after delivery of each dose. Samples were collected pre- and post-illumination and cultured for the hemoflagellates

All preillumination samples exhibited T. cruzi growth in hemoculture, while postillumination samples from units containing 4 and 40 trypomastigotes/mL showed no signs of viable parasites after 16 weeks of culture. In contrast, at both 400 and 4,000 parasites/mL, two of the three units were positive for viable parasites. The total log reduction observed for T. cruzi was 3.5 log or greater, but less than 4.5 log. This level of reduction is likely to be orders of magnitude higher than what would be expected in a tainted blood donation.

The data from the study suggests that the Mirasol System (CaridianBCT; Lakewood, CO, USA) is able to inactivate clinically relevant amounts of T. cruzi in whole blood and it could be a viable alternative to a serologic screening assay. Additionally, this approach would avoid the need for multiple individual screening tests for other agents in a wide spectrum of marginal risks. Considering the challenges associated with T. cruzi testing, the Mirasol System could represent a useful tool in the quest for blood safety, indicating that the system could be effective at preventing transfusion of the causative agent of Chagas disease.

It has been shown that two decades after immigration, 33/52 (63%) of selected blood donors had polymerase chain reaction evidence of parasitemia and three also had culture-confirmed infection. This affirmation that bloodstream parasites are detectable and potentially transmissible, decades after immigration strengthens the rationale for donor screening or whole blood treatment. The study was published in the February 2012 edition of the journal Transfusion.

Related Links:
American Red Cross
CaridianBCT

New
Gold Member
Human Chorionic Gonadotropin Test
hCG Quantitative - R012
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Piezoelectric Micropump
Disc Pump
New
Malaria Test
STANDARD Q Malaria P.f/Pan Ag

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.